Navigation Links
AACR news: New target plus new drug equals death of melanoma cells
Date:4/9/2013

Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.

"It's exciting in that Mer receptor expression correlates so perfectly with disease progression. It's tiered you see a bump in expression as you transition from nevus to melanoma and then again as you transition from melanoma to metastatic disease," says Doug Graham, MD, PhD, investigator at the CU Cancer Center and associate professor of Pediatrics and Immunology at the University of Colorado School of Medicine, the paper's senior author.

After proving this correlation between Mer receptor expression and disease stage in melanoma tissues from clinical patient samples, Graham and colleagues wondered what would happen if they interrupted this Mer signaling. Luckily, the University of North Carolina had recently developed a new compound that did just that UNC1062. The results were dramatic.

"We showed decreased survival signaling, increased apoptosis and decreased growth of the melanoma cells in dishes and in mouse models," Graham says. It seems that Mer receptors are not only correlated with melanoma progression but are in fact driving the aggressiveness of the disease.

"This is the first time there's been an association between Mer and melanoma and the first time to report about this new drug," Graham says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology: